Pfizer is expected to report its second-quarter earnings and investors are hoping the largest U.S. drugmaker will hint whether it is likely later this year to resume its quest to buy British rival AstraZeneca, or perhaps pursue other drugmakers. Investors will be most interested in progress reports on the company's experimental immuno-oncology and hepatitis C drugs. United Parcel Service is ...
News Source
News Source
No comments:
Post a Comment